Business
Retail Offer
CRISM Therapeutics Corporation is undertaking a retail offer to raise up to £100,000 by issuing new ordinary shares at 9 pence per share, with admission expected on December 16, 2025. This offer, alongside a separate placing, aims to fund the company's MHRA-approved Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients. The retail offer is exclusively for eligible investors in the United Kingdom and is conditional on the completion of the placing. Disclaimer*
About this update from Crism Therapeutics Corporation
[{"type":"text","content":"\n\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF CRISM THERAPEUTICS CORPORATION). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION.\n10 December 2025\n\n\nCRISM THERAPEUTICS CORPORATION\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\nRetail Offer to raise up to £100,000\nCRISM Therapeutics Corporation (the \"Company\") is pleased to announce a retail offer via BookBuild (the \"Retail Offer\") of new ordinary shares (\"Ordinary Shares\") of nil par value each in the capital of the Company (the \"Retail Offer Shares\") at an issue price of 9 pence per Retail Offer Share (the \"Issue Price\") to raise up to £100,000.\nIn addition to the Retail Offer, the Company is also conducting a placing of new ordinary shares (the \"Placing Shares\" and together with the Retail Offer Shares, the \"New Ordinary Shares\") at the Issue Price (the \"Placing\" and together with the Retail Offer, the \"Issue\"). A separate announcement has been made regarding the Placing and its terms. For the avoidance of doubt, the Retail Offer is not part of the Placing.\nThe Retail Offer is conditional on the New Ordinary Shares to be issued pursuant to the Retail Offer being admitted to trading on the AIM market operated by the London Stock Exchange (\"Admission...